Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31052201 | 0.91 | ADRB1 (0.40) | ADRB1ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL31052025 | 0.90 | ADRB1 (0.40) | ADRB1ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL31052172 | 0.85 | ADRB1 (0.44) | ADRB1ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL31051873 | 0.85 | ADRB1 (0.57) | ADRB1ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL31052228 | 0.83 | ADRB1 (0.42) | ADRB1HTR1AHTR2C | |
| SCHEMBL31051781 | 0.83 | ADRB1 (0.42) | ADRB1HTR1AHTR2C | |
| SCHEMBL31052048 | 0.83 | ADRB1 (0.42) | ADRB1ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL31051947 | 0.81 | ADRB1 (0.40) | ADRB1ADRA1DADRA1AADRA1BADRA2A | |
| SCHEMBL31052239 | 0.79 | HTR1A (0.47) | ADRA1DADRA1AADRA1BHTR1AADRA2A | |
| SCHEMBL31051951 | 0.79 | ADRB1 (0.65) | ADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678188-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | Ohnishi, Arata (JP) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024185842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | 国立大学法人島根大学 | 2024-09-12 | — | — | WO | disclosed |